Jianjia Robot closes Series B financing
Jianjia Robot completed a Series B financing of more than CNY 100 million from Hillhouse Venture Capital, Fosun Pharma and existing investor BV Baidu Ventures.
Evidence notes
- Hillhouse Venture Capital and Fosun Pharma joined existing investor BV Baidu Ventures in the completed round.
- The capital supported clinical registration and new-product development for Jianjia's joint-replacement surgical robot.
- The financing followed the company's Series A earlier in 2020 and retained Haoyue Capital as exclusive financial adviser.
Company context
Jianjia Medical is a Chinese orthopaedic surgical-robotics company developing Arthrobot and multimodal navigation systems for joint, spine and trauma procedures.